中国医药
中國醫藥
중국의약
CHINA MEDICINE
2009年
3期
229-231
,共3页
王淑平%顾正田%黄燕冰%苏宁
王淑平%顧正田%黃燕冰%囌寧
왕숙평%고정전%황연빙%소저
多囊卵巢综合征%不孕症%克罗米酚%尿促性腺激素
多囊卵巢綜閤徵%不孕癥%剋囉米酚%尿促性腺激素
다낭란소종합정%불잉증%극라미분%뇨촉성선격소
Polycystic ovarian syndrome%Infertility%Clomide%Human menopasual gonadotropin
目的 评估3种促排卵方法治疗多囊卵巢综合征(PCOS)合并不孕症的临床效果.方法 将75例PCOS不孕症患者采用完全随机设计方法分为3组各25例,氯米芬(CC)组给予CC治疗;尿促性素(HMG)组给予HMG方案,CC+HMG组给予CC+HMG序贯治疗.观察3组排卵率、妊娠率及并发症情况.结果 CC组、HMG组和CC+HMG组排卵率分别为61.5%,87.7%,88.1%;妊娠率分别为24%,60%,56%;HMG组和CC+HMG组与CC组相比排卵率及妊娠率均升高,差异有统计学意义(P<0.05).HMG组与CC+HMG组排卵率、妊娠率比较无统计学意义(P>0.05);但多胎妊娠率及卵巢过度刺激综合征(OHSS)发生率比较,HMG组高于CC组和CC+HMG组(P<0.05).结论 采用HMG及CC+HMG序贯方案优于CC的促排卵治疗,CC+HMG方案保证妊娠率的同时可以降低多胎妊娠及OHSS的发生.
目的 評估3種促排卵方法治療多囊卵巢綜閤徵(PCOS)閤併不孕癥的臨床效果.方法 將75例PCOS不孕癥患者採用完全隨機設計方法分為3組各25例,氯米芬(CC)組給予CC治療;尿促性素(HMG)組給予HMG方案,CC+HMG組給予CC+HMG序貫治療.觀察3組排卵率、妊娠率及併髮癥情況.結果 CC組、HMG組和CC+HMG組排卵率分彆為61.5%,87.7%,88.1%;妊娠率分彆為24%,60%,56%;HMG組和CC+HMG組與CC組相比排卵率及妊娠率均升高,差異有統計學意義(P<0.05).HMG組與CC+HMG組排卵率、妊娠率比較無統計學意義(P>0.05);但多胎妊娠率及卵巢過度刺激綜閤徵(OHSS)髮生率比較,HMG組高于CC組和CC+HMG組(P<0.05).結論 採用HMG及CC+HMG序貫方案優于CC的促排卵治療,CC+HMG方案保證妊娠率的同時可以降低多胎妊娠及OHSS的髮生.
목적 평고3충촉배란방법치료다낭란소종합정(PCOS)합병불잉증적림상효과.방법 장75례PCOS불잉증환자채용완전수궤설계방법분위3조각25례,록미분(CC)조급여CC치료;뇨촉성소(HMG)조급여HMG방안,CC+HMG조급여CC+HMG서관치료.관찰3조배란솔、임신솔급병발증정황.결과 CC조、HMG조화CC+HMG조배란솔분별위61.5%,87.7%,88.1%;임신솔분별위24%,60%,56%;HMG조화CC+HMG조여CC조상비배란솔급임신솔균승고,차이유통계학의의(P<0.05).HMG조여CC+HMG조배란솔、임신솔비교무통계학의의(P>0.05);단다태임신솔급란소과도자격종합정(OHSS)발생솔비교,HMG조고우CC조화CC+HMG조(P<0.05).결론 채용HMG급CC+HMG서관방안우우CC적촉배란치료,CC+HMG방안보증임신솔적동시가이강저다태임신급OHSS적발생.
Objective To investigate the effects of three kinds of ovulation induction therapies for patients with Polycystic Ovarian Syndrome (PCOS)related infertility. Methods Seventy-five patients of PCOS related infertility were divided into three groups (group1, 2, 3) randomly. Patients in different groups were treated with Clomide(CC), human menopasual gonadotropin (HMG)and CC + HMG in sequential respectively. The ovulation rates,pregnancy rates and complications were analyzed. Results The ovulation rates were 61.5% ,87.7% and 88. 1% in group 1,2,3. The pregnancy rates were 24% ,60% and 56% in group 1,2,3, with significant difference between group 1 and group 2 or 3 (P < 0.05). There was no difference between group 2 and 3 in ovulation rates or pregnancy rates (P > 0. 05). There was difference of occurrence rates of Ovarian Hyperstimulation Syndrome (OHSS) and twins between group 2 and group 1 or 3 (P < 0.05). Conclusion HMG and CC + HMG are better than CC ovulation induction therapies and CC might decrease the occurrence rates of OHSS and multiple pregnancy.